|
In a major boost to deepen bilateral economic ties and healthcare collaboration, the Kingdom of Saudi Arabia (KSA) is reaching out to Indian pharmaceutical and medical device companies for strategic partnerships and investment in its rapidly expanding healthcare sector.
The Embassy of India in Riyadh, in coordination with Saudi Arabia’s Public Investment Fund (PIF), is organizing an exclusive webinar on August 18, 2025, targeting Indian pharmaceutical and medical device manufacturers. The initiative is part of Saudi Arabia’s broader vision to localize healthcare manufacturing, enhance supply chain resilience, and attract foreign investment under its Vision 2030 framework.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has formally invited its member companies to attend the webinar, highlighting the session as a gateway to gaining insights into regulatory frameworks, procurement mechanisms, and localization incentives offered by the Saudi government.
“Indian pharma companies have been urged to explore key business avenues, regulatory guidance, and potential collaborations with major Saudi Arabia stakeholders including the Public Investment Fund (PIF), the Saudi Food and Drug Authority (SFDA), National Unified Procurement Company (NUPCO), the Ministry of Investment and other healthcare regulators and procurement bodies,” said Raja Bhanu, Director General (DG), Pharmexcil.
“This is a valuable opportunity for Indian exporters to understand Saudi Arabia’s evolving healthcare ecosystem and the emerging prospects for joint ventures, technology transfer, and investment. We urge all member companies to actively participate. Indian companies interested in participating can connect with Lakshmi Prasanna, Senior Director at Pharmexcil, for registration and further details,” the Pharmexcil DG further informed.
Strategic benefits of this collaboration include contribution to national drug security by reducing reliance on imports, expansion of local industrial base and pharmaceutical ecosystem and create high-value jobs and encourage knowledge transfer.
Key growth drivers for these opportunities are increasing demand for chronic disease management, Government incentives and regulatory support for localization and strong potential for regional exports and strategic partnerships with global pharmaceutical players.
These opportunities aim to localize the manufacturing of Active Pharmaceutical Ingredients (APIs), which are the essential raw materials used to produce finished pharmaceutical products. The initiative supports national health security and aims to reduce dependency on imports while supporting Saudi Arabia’s growing pharmaceutical manufacturing capabilities.
Saudi Arabia also seeks to localize the production of Key Starting Materials (KSMs), which are the essential building blocks in the production of Active Pharmaceutical Ingredients (APIs). It is a foundational investment that strengthens the upstream pharmaceutical supply chain, reduces dependency on imports, and contributes to long-term national health security.
There are opportunities of establishing local manufacturing capabilities for small molecule pharmaceutical products in Saudi Arabia. These medicines form the backbone of primary care treatments for chronic and acute conditions and are currently heavily imported. The investment supports healthcare resilience and aligns with national priorities for local production.
Opportunities also involves setting up manufacturing facilities for biologic drugs in Saudi Arabia. Biologics are advanced therapies derived from living organisms, used to treat complex diseases such as cancer, autoimmune conditions, and rare disorders. Localizing production enhances healthcare innovation, quality of care, and biopharma sector competitiveness.
In Medical Devices, opportunities among others are also into the manufacturing of minimally invasive medical tools and devices such as disposable endoscopes, laparoscopic instruments, energy platforms, and associated consumables. The opportunity targets supplying healthcare providers with advanced surgical solutions that enhance precision, reduce recovery time, and improve patient outcomes.
|